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Background: Color Doppler sonography indices, such as resistive index (RI) and pulsatility 
index (PI), can predict arteriosclerosis of internal renal vessels after kidney transplantation. 
Angiotensin II receptor antagonists, however, may have antiatherogenic effects. We therefore 
assessed the effects of losartan on RIs of renal allografts.
Methods: We compared duplex sonographic measurements in renal allograft recipients 
(30 males, 20 females) from living donors randomized to a losartan (25 mg twice daily) or a 
control group.
Results: The patients in the two groups had similar baseline characteristics, and 49 (24 in the 
losartan and 25 in the control group) completed 12 months of follow-up. After 12 months, the 
losartan and control groups did not differ signiﬁ  cantly in mean RI (0.71 ± 0.06 vs 0.69 ± 0.07, 
P = 0.4) or PI (1.3 ± 0.25 vs 1.29 ± 0.28, P = 0.8) of the intrarenal artery and mean RI (0.74 ± 0.07 
vs 0.72 ± 0.07, P = 0.3) and PI (1.5 ± 0.3 vs 1.4 ± 0.34, P = 0.3) of the main artery.
Conclusions: Losartan had no effect on Doppler sonography indices. Longer follow-up, 
however, may be needed to conﬁ  rm this ﬁ  nding.
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Introduction
Chronic allograft nephropathy is characterized by ﬁ  brogenesis or the accumulation of 
extracellular matrix (glomerular, arteriolar, and interstitial), similar to ﬁ  ndings in other 
chronic diseases of the kidneys and other organs.1–3 Histologically, such kidneys show 
evidence of arterial intimal and medial ﬁ  brosis, arteriolar lesions, glomerulosclerosis, 
and interstitial ﬁ  brosis with tubular atrophy. The renin-angiotensin system (RAS) is 
involved in these changes,4 as well as in the initiation and ampliﬁ  cation of atheroscle-
rosis leading to cardiovascular diseases5,6 and mild renal impairment.7 Angiotensin II 
antagonists dramatically decrease atherosclerosis in the cardiovascular system8 and in the 
kidneys.7 Measurements of resistive indices (RIs) of intrarenal arteries of allograft kid-
neys are used to assess intrarenal damage, target organ damage related to hypertension, 
and subclinical atherosclerosis of other organs.9 However, the effects of angiotensin II 
receptor blockers on RIs of allograft kidneys are unclear. We therefore determined the 
effect of losartan on RIs of renal allografts using color Doppler sonography.
Materials and methods
Patients and study design
Between February and May 2006, we screened all consecutive unrelated living renal 
transplant recipients 18 years old who had received transplants at least six months earlier. 
All patients were from the outpatient clinic of the nephrology center at Sadoughi Hospital, 
Sadoughi Medical University in Yazd, Iran. Exclusion criteria included a history of taking Vascular Health and Risk Management 2009:5 98
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angiotensin-converting enzyme inhibitors (ACEIs) and/or 
angiotensin II blockers (ARBs), serum creatinine 2.5 mg/dL, 
serum potassium 5.5 meq/L, 80% stenosis in the main artery 
of the transplanted kidney, and presence of hydronephrosis. 
No patient had a history of smoking. All patients were taking 
cyclosporine and prednisolone, and some were taking myco-
phenolate mofetil (n = 39) or azathioprine (n = 9).
The study protocol was approved by the ethics committee 
of our institution and informed consent was obtained from 
each patient. A randomized clinical trial was performed.
Patients were randomized to receive losartan 50 mg daily 
or no losartan. Patients with hypertension were allowed 
medication, except for ACEIs and ARBs. Blood pressure, 
body mass index (BMI), hematochemical parameters, and 
Doppler sonography indices were evaluated at baseline and 
after six and 12 months of treatment. BMI was calculated as 
weight (kg)/height (m2). Mean arterial blood pressure (MAP) 
and pulse pressure index (PPI; systolic blood pressure – diastolic 
blood pressure/systolic blood pressure) were calculated. Cyclo-
sporine trough levels were measured by an automated clinical 
chemistry analysis system.
Doppler examination
Doppler US examinations, including measurements of RI 
and PI, were performed at least 12 hours after the last dose of 
cyclosporine. All color Doppler examinations were performed 
by a single investigator, blinded to patient treatment, using 
an Aloka SSD-1700 machine with a 3.5-MHz convex-array 
transducer, with the patient in the supine position. Choice of 
using one single investigator for all color Dopppler exami-
nations was to avoid systematic faults. Intrarenal Doppler 
spectra of the interlobar and segmental arteries were obtained 
at three representative locations and spectra of the main 
renal artery were obtained from three points, at the proximal, 
middle, and distal parts. RI was calculated as (peak systolic 
frequency shift – minimum diastolic frequency shift)/peak 
systolic frequency shift; and PI as (peak systolic frequency 
shift – minimum diastolic frequency shift)/mean frequency 
shift. The average RI and PI were computed to yield overall 
RI and PI values for the renal transplants. The criteria for 
signiﬁ  cant (70%) artery stenosis was a ratio 3 of stenotic 
area peak systolic velocity to external iliac artery peak systolic 
velocity, coupled with post-stenotic disturbed ﬂ  ow.
Statistical analysis
A sample population of 25 patients in each group was planned 
to enable achievement of 80% power with α = 0.05 for detect-
ing at least a 10% decrease in RI in the losartan group.10 
All data were analyzed with SPSS 13 (SPSS Inc, Chicago, 
IL, USA). Data are expressed as means ± SDs. Student’s 
t-test for unpaired data, or chi-square analysis, were used as 
appropriate, to assess differences between groups. In addition, 
multiple regression analysis was performed among the study 
groups and other clinical variables.
Results
Between February and May 2006, 68 consecutive patients 
received living renal transplants from unrelated donors. 
Patients were excluded if they had a history of treatment with 
ACEIs or ARBs (n = 12), or serum creatinine 2.5 mg/dL 
(n = 6). None of these patients had 80% stenosis in the 
main renal artery and none had hydronephrosis. Fifty patients 
(30 males, 20 females) were enrolled in the study, with 
25 randomized to losartan and 25 patients to no treatment. 
The follow-up was 12 months; one patient in the losartan 
group was lost to follow-up. One patient in the losartan group 
had hypotension and had to discontinue losartan. During 
follow-up, there were no acute rejection episodes and no 
graft losses.
The two groups had similar baseline characteristics 
(Table 1). The effects of losartan on RI and PI of the intrarenal 
and main arteries after six and 12 months are shown in Table 2. 
Multiple linear regression analysis revealed that losartan had 
no effect on intrarenal RI (P = 0.83) and PI (P = 0.87) after 
adjustment of age, sex, BMI, time since transplantation, dia-
betes, hypertension, MAP, serum creatinine and cyclosporine 
concentration after one year follow-up.
After 12 months, there were no significant differ-
ences between the control and losartan groups in MAP 
(89 ± 15.7 mm Hg vs 90 ± 14.3 mm Hg; P = 0.89), serum cre-
atinine (1.1 ± 0.23 mg/dL vs 1.2 ± 0.34 mg/dL; P = 0.38), serum 
potassium (4.6 ± 0.44 meq/L vs 4.4 ± 0.43 meq/L; P = 0.11), 
and cyclosporine (181 ± 51.3 ng/mL vs 150 ± 57.6 ng/mL; 
P = 0.063) concentrations.
The adverse effects of losartan consisted of hypotension in 
one patient, hyperkalemia in one, and muscle spasm in one.
Some important baseline characteristics (age, sex, BMI, 
time since transplantation, episode of acute rejection before 
study, diabetes, serum creatinine) in twelve patients who 
were excluded because of taking ACEIs and ARBs were not 
signiﬁ  cantly different by comparison with the study patients 
(data is not shown).
Discussion
To our knowledge, this study is the ﬁ  rst to assess the effect 
of an ARB on intrarenal RI and PI. We found, however, Vascular Health and Risk Management 2009:5 99
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that losartan had no effect on intrarenal RI and PI after 
one year.
As previous studies have shown that factors affecting 
intrarenal RI and PI include age, sex, and BMI;9 time since 
transplantation and renal function;11 diabetes;12 and cyclo-
sporine concentration,13 we assessed these factors in our two 
patient groups. Although there were no signiﬁ  cant differ-
ences at baseline between the losartan and control groups in 
these confounding variables, the differences found could be 
clinically relevant inasmuch as the high standard deviations 
indicated huge variations that were related to small sample 
sizes. Therefore, we adjusted the most important factors such 
as age, sex, BMI, time since transplantation, diabetes, serum 
creatinine, and cyclosporine concentration. However, after 
adjustment, losartan had no effect on Doppler sonography 
indices. At the end of trial, the factors such as sex, serum 
creatinine and cyclosporine concentration that could change 
during the study were compared between study groups and 
no differences make sure that these factors did not confound 
the effect of losartan on renal indices. Because of ethical 
issues, we did not perform kidney biopsies at the start of 
treatment; we therefore could not directly determine the 
presence of high RI. Randomization likely eliminated any 
other confounding variables.
RI of transplanted kidneys has been found to correlate with 
histologically proven arteriolosclerosis of the internal renal 
vessels,14,15 and PI  0.7 in transplanted kidneys has been 
found to correlate with a higher incidence of arteriosclerosis.15 
Table 2 Doppler sonography indices in the losartan and control groups











 RI 0.7 ± 0.06 0.69 ± 0.08 0.8 0.72 ± 0.07 0.72 ± 0.07 0.9
 PI 1.2 ± 0.3 1.3 ± 0.4 0.3 1.4 ± 0.3 1.4 ± 0.32 0.8
6 months
 RI 0.72 ± 0.06 0.7 ± 0.06 0.2 0.75 ± 0.04 0.73 ± 0.07 0.19
 PI 1.4 ± 0.3 1.4 ± 0.3 0.7 1.57 ± 0.28 1.54 ± 0.3 0.7
12 months
 RI 0.71 ± 0.06 0.69 ± 0.07 0.4 0.74 ± 0.07 0.72 ± 0.07 0.3
 PI 1.3 ± 0.25  1.29 ± 0.28 0.8 1.5 ± 0.3 1.4 ± 0.34 0.3
Abbreviations: RI, resistive index; PI, pulsatility index.
Note: aOne patient in the losartan group was lost to follow-up.
Table 1 Baseline characteristics of patients
Characteristic Losartan group (n = 25) Control group (n = 25) P value
Age (years) 36 ± 12 42 ± 14 0.1
Male sex: no (%) 12 (48%) 18 (72%) 0.083
Male donor sex: no (%) 20 (80%) 23 (92%) 0.29
BMI 24.7 ± 4.7 25.6 ± 3.9 0.3
Time since transplant (months) 47 ± 36 44 ± 24 0.6
Episode of AR before study: no (%) 1 (4%) 3 (12%) 0.6
Diabetes: no (%) 3 (12%) 1 (4%) 0.3
Hypertension: no(%) 13 (52%) 12 (48%) 0.7
MAP (mmHg) 99 ± 10.5 97 ± 10 0.33
Serum creatinine mg/dL 1.2 ± 0.3 1.2 ± 0.3 0.9
Serum potassium meq/L 4.3 ± 0.4 4.5 ± 0.4 0.4
Cyclosporine level (ng/mL) 187 ± 67 204 ± 75 0.9
Abbreviations: AR, acute rejection; BMI, body mass index; MAP, mean arterial pressure.Vascular Health and Risk Management 2009:5 100
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ARBs have been found to show antiatherogenic effects.8,16 
For example, ARBs had a regressive effect on the formation 
of fatty streaks in monkeys.17
Little is known about the effects of ACEIs on intrarenal 
RI and PI. ACEIs have been found to reduce PI in normoten-
sive individuals,18 and lisinopril has been found to decrease 
10% of renal RI (from 0.61 ± 0.02 to 0.56 ± 0.04) in hyper-
tensive patients after two years follow-up.10 We could not 
show the decrease of RI after one year follow-up and it might 
be due to short follow-up. However, to our knowledge, there 
have been no studies on the effects of ARBs or ACEIs on 
renal Doppler indices in allograft kidneys.
Conclusion
Although we expected that ARBs would decrease intrarenal 
RI and PI, we did not observe this effect, which suggests that 
longer follow-up and larger sample sizes are required.
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